Arovella Therapeutics Limited
1 day chart
Get A$10 trading credit to start you off
Sign up and fund a new Stake AUS account and enjoy an extra A$10 trading credit on us.
Sign up and fund a new Stake AUS account and get A$10 bonus trading credit.
T&Cs apply
About ALA
Arovella Therapeutics Limited (ALA, formerly Suda Pharmaceuticals Ltd) is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The Company's product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types.
Find out what a historical investment in Arovella Therapeutics Limited would be worth today using our ALA stock calculator.
Sector
Health Care
CEO
-
Industry
Pharmaceuticals
Website
arovella.com
$117M
-10.22
-
$0.10
$0.09
$0.09
$0.21
$0.07
Ready to start your investing journey with Stake?
Open an accountAnnouncements
ALA FAQs
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in ALA
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in ALA
on Stake
Buy ALA from A$3 brokerage
Invest in 2,500+ Aussie stocks and ETFs
CHESS-sponsored ASX trades
